EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer

Andrew C Johns, Mike Yang, Lai Wei, Madison Grogan, Daniel Spakowicz, Sandipkumar H Patel, Mingjia Li, Marium Husain, Kari L Kendra, Gregory A Otterson, Ashley E Rosko, Barbara L Andersen und 3 weitere

The Oncologist · 2023

DOI: 10.1093/oncolo/oyad097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2023. Verfasst von Andrew C Johns und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS, Ohio State University Center for Clinical and Translational Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Immune checkpoint inhibitor immunotherapy (IO) is revolutionizing cancer care but can lead to significant toxicity. This study seeks to describe potential risk factors for immune-related adverse events (irAEs) specifically among older adults. Materials and Methods This was a retrospective study at a single academic comprehensive cancer center based on chart review data abstracted by physicians. For patients aged ≥70 years, frequency, type, and grade of irAEs and their association with baseline patient demographics, comorbidities, mobility, and functional status were characterized using bivariate analysis. Based on those results, multivariable logistic regressions were constructed to model the association between these characteristics with any grade and grade 3 or higher irAEs.

Results

Data were analyzed for 238 patients aged ≥70 years who received IO for mostly (≥90%) advanced cancer between 2011 and 2018. Thirty-nine percent of older adults experienced an irAE and 13% experienced one that was grade 3 or higher. In the multivariable analysis, depression was associated with an increased incidence of any grade irAE, while decreased life-space mobility was associated with an increased incidence of grade ≥3 irAEs.

Conclusion

Most characteristics of special interest among older adults, include fall risk, weight loss, cognitive limitations, and hearing loss, were not associated with irAEs in our study. However, decreased life-space mobility and depression are potential risk factors for IO toxicity among older adults with advanced cancer. Interventions designed to evaluate and mitigate modifiable risk factors for treatment-related toxicity are needed, and the results of this study may be useful for guiding those efforts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, ImmunologicalNeoplasmsHumansAgedImmune Checkpoint InhibitorsRetrospective StudiesRisk FactorsImmunotherapy

Stichwörter der Autor:innen

checkpoint inhibitorgeriatricsimmune-related adverse eventsimmunotherapytoxicity

Substanzen

Immune Checkpoint InhibitorsAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
  • College of Medicine, The Ohio State University, Columbus, OH, USA.
  • Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA.
  • Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
  • Division of Hospital Medicine, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
  • Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

ORCID-Profile: Carolyn J Presley

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS
  • Ohio State University Center for Clinical and Translational Science
  • Clinical Faculty Investigators
  • National Institute of Aging
  • National Center for Advancing Translational Sciences
  • Ohio State University Comprehensive Cancer Center
  • National Institutes of Health

Zitieren

APA

Johns, A. C., Yang, M., Wei, L., Grogan, M., Spakowicz, D., Patel, S. H., Li, M., Husain, M., Kendra, K. L., Otterson, G. A., Rosko, A. E., Andersen, B. L., Carbone, D. P., Owen, D. H., & Presley, C. J. (2023). Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer. The Oncologist. https://doi.org/10.1093/oncolo/oyad097

Vancouver

Johns AC, Yang M, Wei L, Grogan M, Spakowicz D, Patel SH, et al. Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer. The Oncologist. 2023. doi:10.1093/oncolo/oyad097

BibTeX
@article{Johns2023,
  author = {Johns, Andrew C and Yang, Mike and Wei, Lai and Grogan, Madison and Spakowicz, Daniel and Patel, Sandipkumar H and Li, Mingjia and Husain, Marium and Kendra, Kari L and Otterson, Gregory A and Rosko, Ashley E and Andersen, Barbara L and Carbone, David P and Owen, Dwight H and Presley, Carolyn J},
  title = {Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyad097}
}
Kostenlos starten →